Kiadis Pharma Receives Regulatory Approval From Health Canada for a Phase II Clinical Study With Its Blood Cancer Treatment ATIR™
2/26/2013 11:23:36 AM
More...
|
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
1/22/2013 10:34:55 AM
More...
|
Kiadis Pharma Raises $12.8 Million in Financing Round
11/20/2012 7:16:14 AM
More...
|
Kiadis Pharma Signs License Agreement with Hospira, Inc. (HSP) to Commercialize ATIR(TM) in Europe and Asia
1/4/2011 9:05:54 AM
More...
|
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
7/8/2010 8:46:54 AM
More...
|
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
11/30/2009 8:23:28 AM
More...
|
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium
4/8/2009 9:19:36 AM
More...
|
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
1/6/2009 11:49:46 AM
More...
|
Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
12/8/2008 8:43:27 AM
More...
|
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations Kiadis Pharma Proceeds With Pivotal Trial ATIR(TM)
12/4/2008 9:46:09 AM
More...
|
|